核心观点在2025年ASCO大会上,公司核心产品Lisaftoclax展示了在维奈克拉耐药后患者中的研究结果。在28例既往接受维奈克拉治疗的患者中,22例可评估疗效患者的ORR为31.8%,其中22.8%的患者CR/Cri,同时在15例CMML患者中,ORR为80%。整体看,产品Lisaftoclax在维奈克拉耐药后的肿瘤患者中展现了优异疗效,产品基本面良好,安全性优异,看好药物后续临床进展以及...
Source Link核心观点在2025年ASCO大会上,公司核心产品Lisaftoclax展示了在维奈克拉耐药后患者中的研究结果。在28例既往接受维奈克拉治疗的患者中,22例可评估疗效患者的ORR为31.8%,其中22.8%的患者CR/Cri,同时在15例CMML患者中,ORR为80%。整体看,产品Lisaftoclax在维奈克拉耐药后的肿瘤患者中展现了优异疗效,产品基本面良好,安全性优异,看好药物后续临床进展以及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.